Antifungal Therapy in Patients with Comorbidities

Safety and Efficacy of Topical Antifungals

Topical ketoconazole is safe for patients with hypertension, diabetes, and obesity, with minimal systemic absorption and no significant interactions with medications used to treat these conditions, as per British Journal of Dermatology guidelines 1, 2, 3
Topical ketoconazole is preferred for diabetic patients with fungal infections, as it avoids the risk of drug interactions with oral hypoglycemic agents, with up to one-third of diabetic patients having onychomycosis 1
Topical ketoconazole is effective for mild-to-moderate localized fungal infections, particularly useful when risk of drug interaction is considered high, as stated by the British Journal of Dermatology guidelines 1
If oral antifungal therapy becomes necessary, terbinafine is preferred over azoles in diabetic patients due to lower risk of drug interactions, according to the British Journal of Dermatology guidelines 1

Topical ketoconazole should not be used on broken or severely inflamed skin, as this may increase systemic absorption 1
For extensive or systemic fungal infections, topical therapy alone may be insufficient, and oral antifungal therapy may be necessary, with itraconazole or fluconazole preferred due to their better safety profiles, as recommended by the Infectious Diseases Society of America 4

No special monitoring required for topical formulations, regular assessment of treatment response is sufficient, as recommended by the British Journal of Dermatology guidelines 1
Regular use of topical ketoconazole wash may help prevent recurrence of fungal infections, particularly important in diabetic patients 1
Ketoconazole carries a black box warning from the FDA for serious hepatotoxicity, with liver enzyme elevations occurring in 10-20% of patients, typically within the first 6 months of treatment, and weekly monitoring of liver function tests is recommended by the FDA for patients on ketoconazole 5
Monitoring for symptoms of adrenal insufficiency, such as fatigue, weakness, dizziness, and nausea, is recommended when using ketoconazole, with a strength of evidence classified as "high" 5

The American Heart Association recommends first-line treatment with an ACE inhibitor or ARB for patients with diabetes and hypertension, with a target blood pressure of <130/80 mmHg, and adding a thiazide-like diuretic and/or dihydropyridine calcium channel blocker if blood pressure target is not achieved, as recommended by the American Diabetes Association 6, 7
The American College of Cardiology recommends avoiding β-blockers as first-line agents in patients with obesity, and instead opting for alternative agents such as ACE inhibitors or ARBs, with statin therapy recommended for patients with multiple cardiovascular risk factors 6, 8
Lifestyle modifications, including weight loss, DASH dietary pattern, sodium restriction, and increased physical activity, are recommended to reduce cardiovascular risk, with a strength of evidence classified as "strong" 9
The American Diabetes Association recommends continuing appropriate diabetes management with target A1C as close to normal as possible without significant hypoglycemia, and monitoring renal function and potassium levels within 3 months after starting ACE inhibitors, ARBs, or diuretics 7